Jump to any asset
849 assets, updated daily
As of September 27, 2026, CVS Health Corporation (CVS) trades at $89.13. CleaRank Financial AI rates it Sell with a fair value of $89.13, in line with the current price. Wall Street's consensus target is $116.00 across 27 analysts. RSI at 28 is in oversold territory, and the price is below its 50-day average of $97.07.
CVS Health Corporation (CVS)
CVS Health Corporation NYSE
$89.13
4.080 (4.80%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
21 / 100
CVS Health Corporation (CVS) is trading at $89.13, below its 50-day Simple Moving Average (SMA) of $97.07 and showing oversold conditions with an RSI of 28.32. The company's consensus rating is a Sell, driven by substantial insider selling totaling $577.9 million against only $100,000 in purchases, indicating a lack of confidence from management. While Wall Street maintains a Buy consensus with a median price target of $116.00, suggesting a 30.1% upside, the overwhelming insider divestiture and bearish technicals present a compelling case for caution. Fundamental analysis shows CVS Health trading at a Price-to-Earnings (P/E) ratio of 23.52, which is below the sector median of 31.9, and a Price-to-Sales (P/S) ratio of 0.28, also below the sector median of 3.7. However, its Return on Equity (ROE) of 6.21% and Net Profit Margin of 1.18% lag behind sector averages. The company's Debt-to-Equity ratio stands at 0.96, aligning with the sector average. Despite these valuation advantages relative to peers, the significant insider selling and weak technical indicators overshadow the fundamental picture.
CVS Price Analysis
Market Metrics
Open
$85.35
Day Range
$84.70 to $89.35
Prev Close
$85.05
Volume
15.77M
52-Week Range
$69.51 to $110.68
Market Cap
$113.99B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-26%), which may indicate undervaluation or specific company headwinds.
CVS Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, CVS beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats.
CVS Analysis
Company's Health
2/5
AI Technical Analysis
CVS Health Corporation's stock is currently exhibiting bearish momentum, trading below its 50-day SMA of $97.07 and its 20-day Exponential Moving Average (EMA) of $91.42, though it remains above its 200-day SMA of $87.51. The Relative Strength Index (RSI) is significantly oversold at 28.32, suggesting potential for a short-term bounce, but the MACD at -2.68 indicates a prevailing downward trend. The stock has experienced a significant decline, moving from above its 50-day SMA to below it, signaling a shift in short-term sentiment. Key support levels are being tested, with the 200-day SMA at $87.51 acting as a critical floor. Resistance is now established at the 50-day SMA ($97.07) and the 20-day EMA ($91.42). Volume has been elevated, with the latest volume at 15.77 million, 65.4% above the average, indicating strong selling pressure. The current chart structure points towards continued weakness unless a significant catalyst emerges to reverse the oversold conditions and insider selling trend.
ProTips
- Monitor insider transactions closely; the current heavy selling pressure from officers and directors is a significant bearish signal that overrides positive analyst targets.
- Given the oversold RSI of 28.32, traders may look for a short-term bounce, but the prevailing trend and insider activity suggest caution against long positions.
- Consider the dividend yield of 2.98% as a potential support, but be aware that the overall negative sentiment and insider selling could impact future dividend sustainability.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold $577.9 million worth of CVS Health Corporation stock against minimal purchases of $100,000, indicating a strong lack of confidence in the company's future prospects.
Source: Insider TransactionsBearish
Oversold Technical Conditions
The stock's RSI is significantly oversold at 28.32, and it is trading below key moving averages (50-day SMA and 20-day EMA), suggesting potential for further price declines despite the oversold status.
Source: Technical AnalysisBullish
Positive Earnings Surprises
CVS Health Corporation has consistently beaten EPS estimates in recent quarters, demonstrating operational efficiency in meeting or exceeding analyst expectations.
Source: Earnings ReportsBullish
Attractive Valuation Relative to Peers
The company's P/E ratio of 23.52 and P/S ratio of 0.28 are below sector medians, suggesting potential undervaluation compared to other healthcare companies.
Source: Fundamental AnalysisMarket Outlook
The base case outlook for CVS Health Corporation over the next 6-12 months is cautious, with the stock facing headwinds from heavy insider selling and oversold technical conditions. While the median analyst price target suggests an upside of 30.1% to $116.00, the current consensus rating is Sell due to these negative signals. The stock's ability to break above its 50-day SMA of $97.07 and sustain momentum will be critical for a bullish reversal. Potential catalysts for a positive shift could include a significant improvement in profit margins, a reversal in insider selling trends, or positive news regarding strategic initiatives. Conversely, continued insider divestiture, failure to break key resistance levels, or worsening profitability could lead to further downside, potentially testing the 200-day SMA at $87.51 and beyond, as indicated by the long-range projection's downside scenario of $46.93 by 2030.
Key Statistics
| Market Cap | 113.99B |
|---|---|
| P/E Ratio | 23.52 |
| EPS (TTM) | 3.79 |
| Dividend Yield | 2.98% |
| 52 Week High | 110.68 |
| 52 Week Low | 69.51 |
CVS Health Corporation presents a mixed fundamental picture, with a P/E ratio of 23.52 and a P/S ratio of 0.28 that appear attractive when compared to sector medians of 31.9 and 3.7, respectively. This suggests the stock may be undervalued on a relative basis. However, the company's profitability metrics are concerning, with a Net Profit Margin of 1.18% and an ROE of 6.21%, both significantly below the healthcare sector averages. The Debt-to-Equity ratio of 0.96 is in line with the sector. While the company's valuation multiples are lower than its peers, the lagging profitability and a substantial amount of insider selling raise questions about the sustainability of its current price. The forward revenue growth estimates for the current year are projected at +4.00%, and for next year at +3.00%, indicating modest expansion. The company's ability to improve its profit margins and generate stronger returns will be critical for justifying its current valuation, especially in light of the negative insider sentiment.
Earnings & Growth Analysis
CVS Health Corporation recently reported strong EPS beats in its latest quarters, with the quarter to June 2026 showing an actual EPS of $2.58 against an estimate of $1.85, a 39.46% surprise, although the stock reacted negatively with a -2.93% price change. Prior quarters also showed positive surprises, including a 16.29% beat in the quarter to March 2026 and a 16.15% beat in the quarter to December 2025. Despite these consistent earnings beats, the market reaction has been muted or negative, suggesting that the positive earnings surprises are not translating into sustained stock price appreciation.
Key Risks
The most significant risk for CVS Health Corporation is the overwhelming insider selling, with over $577 million in sales against minimal purchases, signaling a strong lack of confidence from management. Additionally, the stock is exhibiting significantly oversold technical conditions with an RSI of 28.32 and is trading below key moving averages, indicating potential for further downside pressure. The company's profitability metrics, including a low net profit margin of 1.18%, also present a risk if they do not improve relative to sector peers.
Technical Indicators
| RSI (14) | 28.32 |
|---|---|
| MACD | -2.68 |
| SMA 50 | 97.07 |
| SMA 200 | 87.51 |
RSI
Oversold
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($97.07) above the 200-day SMA ($87.51), price is trading below the 50-day SMA, RSI at 28.3 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.14
Weak correlation
Nasdaq 100 (QQQ)
+0.06
Weak correlation
Bitcoin (BTC)
-0.01
Weak correlation
Gold (XAU)
-0.02
Weak correlation
Check Custom Correlation
How does any other asset move with CVS? One year of daily closes, Pearson correlation.
Try
CVS Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Short entry pick an entry style
Conservative
$90.91
2% above current price
Lower risk, wait for rally
Aggressive
$89.13
Short at current price
Higher risk, chasing the move
Risk Management
STOP LOSS
$99.15
MAX LOSS
-9.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (28.3) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$86.37
-5% (Conservative)
-3.1% (Aggressive)
TARGET 2
$81.82
-10% (Conservative)
-8.2% (Aggressive)
TARGET 3
$77.28
-15% (Conservative)
-13.3% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for CVS is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in CVS in September 2016 would be worth about $9,842 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CVS today could grow to about $13,543 by 2036 in the base case, with a bull case near $45,231 and a bear case around $4,055. Projections are statistical simulations, not guarantees.
CVS Stock Price Prediction: 2030
CleaRank's simulation projects a price near $101 for CVS by 2030 in the base case, from $89.13 today (1.1x over 4 years). The downside path ends near $46.93. These are outcomes of a Monte Carlo simulation run on CVS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $62.75 | $91.87 | $135 |
| 2028 | $55.23 | $94.70 | $162 |
| 2029 | $50.43 | $97.62 | $189 |
| 2030 | $46.93 | $101 | $216 |
| 2031 | $44.21 | $104 | $243 |
| 2032 | $42.01 | $107 | $272 |
| 2033 | $40.19 | $110 | $302 |
| 2034 | $38.64 | $114 | $334 |
| 2035 | $37.30 | $117 | $368 |
| 2036 | $36.14 | $121 | $403 |
Method: 10,000 simulated price paths using CVS's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
CVS Insider Trading Analysis
Bought
$100.0K
1 Transactions
Sold
$577.9M
4 Transactions
Insiders
21
Active Traders
Avg Transaction
$115.6M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | ROBBINS LARRY
Director
|
Sell | 3.4M | $317.5M |
| May 6, 2025 | ROBBINS LARRY
Director
|
Sell | 3.8M | $253.7M |
| Mar 26, 2021 | MERLO LARRY J
Director
|
Sell | 270.7K | $20.2M |
| Jan 15, 2020 | MERLO LARRY J
Chief Executive Officer
|
Sell | 266.5K | $19.9M |
| Aug 4, 2022 | LOTVIN ALAN M
Officer
|
Sell | 143.4K | $14.2M |
| Dec 15, 2022 | MORIARTY THOMAS M
General Counsel
|
Sell | 137.5K | $13.5M |
| Jun 28, 2022 | MORIARTY THOMAS M
General Counsel
|
Sell | 138.7K | $13.2M |
| Jan 8, 2019 | MERLO LARRY J
Chief Executive Officer
|
Sell | 166.4K | $11.5M |
| Feb 1, 2019 | MERLO LARRY J
Chief Executive Officer
|
Sell | 166.4K | $10.7M |
| Nov 3, 2021 | ROBERTS JONATHAN C
Officer
|
Sell | 108.9K | $10.3M |
Page 1 of 1
Frequently Asked Questions
Is CVS Health Corporation stock a buy right now?
CVS Health Corporation is currently rated a Sell based on our consensus score of 21, primarily due to heavy insider selling and oversold technicals. While Wall Street analysts maintain a Buy consensus with a median price target of $116.00, the significant negative insider activity and bearish chart patterns suggest caution is warranted.
What is CVS Health Corporation's stock price forecast for 2030?
Based on Monte Carlo simulations, CVS Health Corporation's stock price forecast for 2030 shows a base case of $100.63, with a downside projection of $46.93 and an upside projection of $215.74. These are statistical outcomes and not definitive price targets.
What are the biggest risks facing CVS Health Corporation?
The primary risks for CVS Health Corporation include substantial insider selling exceeding $577 million, which signals a lack of management confidence, and significantly oversold technical conditions with an RSI at 28.3. Also, the company's profit margins are below sector averages, posing a risk to future performance.
How does CVS Health Corporation's valuation compare to its sector?
CVS Health Corporation's P/E ratio of 23.52 and P/S ratio of 0.28 are lower than the healthcare sector medians of 31.9 and 3.7, respectively, suggesting a potentially attractive valuation. However, its ROE of 6.21% and profit margin of 1.18% lag behind sector averages.
What is the current technical outlook for CVS Health Corporation stock?
The technical outlook for CVS Health Corporation is bearish, with the stock trading below its 50-day SMA and 20-day EMA, and showing oversold RSI levels. Key support is at the 200-day SMA of $87.51, while resistance is at the 50-day SMA of $97.07.
What is the consensus rating for CVS Health Corporation stock?
The consensus rating for CVS Health Corporation stock is Sell, with a consensus score of 21 out of 100. This is driven by significant insider selling and bearish technical indicators, despite a generally positive Wall Street analyst consensus.
How has CVS Health Corporation performed in recent earnings reports?
CVS Health Corporation has consistently beaten EPS estimates in recent quarters, including a significant 39.46% surprise in the quarter to June 2026. However, the stock price has reacted negatively to these beats, indicating that earnings performance is not currently driving positive market sentiment.
Are there any notable institutional holders or activist investors in CVS Health Corporation?
While the provided data does not detail specific institutional holders or activist investors, the significant insider selling by officers and directors is a key factor to monitor. The total insider sales amount to $577.9 million, which is a strong signal of potential concern.